SCHEDULE 13D/A: Fosun Pharma USA Divests Significant Stake in Nature's Sunshine Products, Ceasing Majority Ownership

Fosun Pharma USA Inc. has completed the sale of over 2.8 million shares of Nature's Sunshine Products Inc. common stock, reducing its beneficial ownership to below 5%.

Summary

• Fosun Pharma USA Inc. (FPUSA), a reporting person, sold 2,854,607 shares of Nature's Sunshine Products Inc. (NSP) Common Stock.
• The shares were sold at a public offering price of $12.00 per share, with net proceeds to FPUSA of $11.46 per share after underwriting discounts and commissions of $0.54 per share.
• The offering closed on June 27, 2025.
• Following the sale, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) beneficially owns 64,167 shares of NSP Common Stock, representing 0.35% of the outstanding shares.
• As of June 27, 2025, the Reporting Persons (Fosun Pharma and FPUSA) ceased to be beneficial owners of more than five percent of NSP's issued and outstanding Common Stock.
• The sale was conducted pursuant to NSP's shelf registration statement on Form S-3, which became effective on June 18, 2025.
• FPUSA entered into a lock-up agreement, agreeing not to sell or transfer any additional NSP securities for 90 days from June 27, 2025.
• NSP entered into a share repurchase agreement with FPUSA, allowing NSP to purchase up to $15.0 million of the shares from the Underwriter as part of its previously announced share repurchase program.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a major shareholder significantly reducing its stake, which can be perceived as a lack of long-term conviction. However, the company's potential share repurchase program offers some mitigating positive sentiment.

Positives

• FPUSA successfully monetized a significant portion of its investment in Nature's Sunshine Products Inc., generating substantial cash proceeds.
• Nature's Sunshine Products Inc. has the option to repurchase up to $15.0 million of the shares sold, which could be viewed positively by investors as a use of capital to support share price.

Negatives

• A major shareholder, Fosun Pharma USA Inc., significantly reduced its stake in Nature's Sunshine Products Inc., potentially signaling a reduced long-term strategic interest.
• The sale of a large block of shares (2,854,607 shares) could introduce selling pressure on Nature's Sunshine Products Inc.'s stock in the short term.

Risks

• The market may interpret the significant reduction in ownership by a major strategic investor as a negative signal, potentially impacting investor confidence and share price.
• The expiration of the 90-day lock-up period on September 25, 2025, could lead to further sales by FPUSA, potentially creating additional downward pressure on the stock.

Future Outlook

Fosun Pharma USA Inc. is subject to a 90-day lock-up agreement, restricting further sales or transfers of Nature's Sunshine Products Inc. securities until approximately September 25, 2025. Nature's Sunshine Products Inc. retains the option to purchase up to $15.0 million of the offered shares from the Underwriter.

Industry Context

This transaction represents a significant divestment by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a global healthcare company, from Nature's Sunshine Products Inc., a company operating in the health and wellness sector, specifically in nutritional and herbal products. This move suggests a strategic re-evaluation of the investment by Fosun Pharma, potentially to reallocate capital or streamline its portfolio, rather than a direct reflection on the operational performance of Nature's Sunshine Products Inc. The health and wellness industry continues to see shifts in investor interest and strategic partnerships.

Comparison to Industry Standards

• This document primarily details a secondary offering by a selling shareholder and a change in beneficial ownership, rather than the operational or financial performance of Nature's Sunshine Products Inc. As such, direct comparisons to industry-standard financial metrics or project results of comparable companies are not applicable based solely on the content of this filing.
• The transaction involves a large block sale, which is a common mechanism for institutional investors to divest significant stakes. The pricing of the offering at $12.00 per share, with a standard underwriting discount, aligns with typical market practices for such secondary offerings.

Related Party Transactions

• The Share Repurchase Agreement between Nature's Sunshine Products Inc. and Fosun Pharma USA Inc. (a former significant shareholder) allows the Issuer to purchase shares from the Underwriter, which can be considered a related party transaction given the historical relationship and the nature of the offering.

Stakeholder Impact

• **Shareholders:** Existing shareholders may experience potential downward pressure on share price due to the large block sale, but also potential support from the company's share repurchase program. New investors acquired shares at $12.00.
• **Fosun Pharma USA Inc.:** Received significant cash proceeds from the sale of its shares.
• **Nature's Sunshine Products Inc.:** The company's ownership structure has changed, with a major strategic investor significantly reducing its stake. The company has the option to utilize its share repurchase program to mitigate market impact.

Next Steps

• Expiration of the 90-day lock-up period for Fosun Pharma USA Inc. on or about September 25, 2025.
• Potential execution of the share repurchase by Nature's Sunshine Products Inc. of up to $15.0 million of shares from the Underwriter.

Key Dates

Recommendation

Keywords

Nature's Sunshine Products, Fosun Pharma, SEC filing, Schedule 13D, share sale, secondary offering, beneficial ownership, lock-up agreement, share repurchase, divestment, healthcare, nutritional supplements